Benefiting from 15 years of expertise in protein production, the protein science platform within WuXi Biology has successfully served hundreds of global clients. Our protein science specialists are at the forefront of drug discovery efforts, offering a wide range of services including protein production, isotope labeling, and customized conjugation across all major target classes. We …Read More >

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we share with you our experience in the establishment and antitumor efficacy evaluation of adenovirus vaccine AD5-HPV. https://onco.wuxiapptec.com Introduction: Adenoviruses (Ad) are non-enveloped …Read More >

Introduction: Targeted Protein Degradation (TPD) has emerged as a promising therapeutic modality due to its potential to develop therapeutics for previously undruggable targets and address the resistance issues of small molecule inhibitors. Central to this strategy is the novel protein-degradation approach represented by proteolysis-targeting-chimeras (PROTACs), which induce targeted protein degradation through the ubiquitin-proteasome system (UPS). …Read More >

Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted therapy, and immunotherapy, all of which inhibit tumor growth. However, an inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. Unraveling the underlying mechanisms of resistance is pivotal in overcoming …Read More >

Introduction: Cancer is a major public health concern, and this disease is a leading cause of death worldwide. There are over 200 different types of cancer, and such complexity has slowed the rate of progress being made by researchers. Encouragingly, the emergence of immunotherapies, especially tumor vaccines, brings hope to cancer patients. Personalized tumor vaccines …Read More >

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our large-scale cell panel screening platform for integrated pharmacogenomics and bioinformatics research. Cell viability assessment is a commonly used in …Read More >

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Read our newest case study on enhancing predictivity of drug-target interactions. In collaboration with Cyclica, WuXi AppTec scientists engaged in a study to understand the synergies between DNA encoded library (DEL) screening and Cyclica’s MatchMaker™ deep-learning model for protein-ligand interactions. Our findings indicate that combining experimental DEL data with computational analysis from MatchMaker™ can lead …Read More >